Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrx/Aventis Cardizem CD Class Action Appeal Pending; State AGs Sue

Executive Summary

Andrx' appeal of a Detroit federal court summary judgment in a Cardizem CD antitrust class action suit could be decided by the end of the year.

You may also be interested in...



AARP Health Litigation Brief Supports Michigan Supplemental Rebates

AARP's litigation team has filed an amicus brief supporting use of supplemental rebates in the Michigan Medicaid program

AARP Health Litigation Brief Supports Michigan Supplemental Rebates

AARP's litigation team has filed an amicus brief supporting use of supplemental rebates in the Michigan Medicaid program

Senate Rx Patent Settlement Bill Revised To Limit Reporting Requirements

The revised version of Sen. Patrick Leahy's (D-Vt.) patent settlement notification bill (S 754) would limit the types of generic-brand agreements that would need to be reported to antitrust agencies.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel